Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

NCT02434744 is registered in ClinicalTrials.gov with Response Pharmaceuticals as lead sponsor.

NCT NCT02434744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02434744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Response Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
March 31, 2016
Enrollment
121 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus